Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis

J Trone; J Ollier; C. Chapelle; J Bertoletti; E Cucherat; J Mismetti; E Magné; J Laporte

doi:10.1093/annonc/mdy035

Journal Articles Annals of Oncology Year : 2018

Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis

, , (1) , , , , ,

1

J Trone

Function : Author

J Ollier

Function : Author

C. Chapelle

Function : Author

Groupe de recherche sur la thrombose

J Bertoletti

Function : Author

E Cucherat

Function : Author

J Mismetti

Function : Author

E Magné

Function : Author

J Laporte

Function : Author

Domains

Life Sciences [q-bio] Pharmaceutical sciences Pharmacology

Michel Cucherat : Connect in order to contact the contributor

https://hal-hcl.archives-ouvertes.fr/hal-02112951

Submitted on : Saturday, April 27, 2019-1:11:58 PM

Last modification on : Monday, December 12, 2022-5:26:11 PM

Dates and versions

hal-02112951 , version 1 (27-04-2019)

Identifiers

HAL Id : hal-02112951 , version 1
DOI : 10.1093/annonc/mdy035

Cite

J Trone, J Ollier, C. Chapelle, J Bertoletti, E Cucherat, et al.. Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis. Annals of Oncology, 2018, 29 (4), pp.803-811. ⟨10.1093/annonc/mdy035⟩. ⟨hal-02112951⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

UNIV-ST-ETIENNE HCL UDL

24 View

0 Download

Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis

Domains

Dates and versions

Identifiers

Cite

Export

Collections

Altmetric

Share